Methotrexate is a Small Molecule owned by medac, and is involved in 17 clinical trials, of which 13 were completed, and 4 are ongoing.

Methotrexate affects both the infammatory and immunosuppressive aspects of response. It is effective in the treatment of rheumatoid arthritis and decreases the rate of formation of new bony erosions. It inhibits proliferation of the lymphocytes and other cells responsible for inflammation in the joint, in case of  rheumatoid arthritis. It involves in normalization of low interleukin-2 (IL-2) through an effect on polyamine synthesis, reduced IgM-rheumatoid factor (RF) production, decreased IL-1 production, secretion or binding, and decreased IL-6 activity.

The revenue for Methotrexate is expected to reach a total of $440m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Methotrexate NPV Report.

Methotrexate is currently owned by medac. Medexus Pharmaceuticals is the other company associated in development or marketing of Methotrexate.

Methotrexate Overview

Methotrexate (Metoject/ Rasuvo/ Metex/ Metoject Pen/ Trexject, Metotab) is an pterin derivative acts as antineoplastic antimetabolite with immunosuppressant properties. It is formulated as solution for subcutaneous, intramuscular, Intraarterial, intravenous route and tablets for oral route of administration. Methotrexate is indicated for the treatment of active rheumatoid arthritis in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis, severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids and severe psoriatic arthritis in adult patients.

It is also under development for the treatment for rheumatoid arthritis and psoriasis in China and acute lymphoblastic leukaemia (ALL).

Medexus Pharmaceuticals Overview

Medexus Pharmaceuticals (MDI) is a pharmaceutical company with a focus on the therapeutic areas of rheumatology, specialty oncology, auto-immune disease, allergy, and pediatric diseases. It provides prescription and over the counter brands to patients and healthcare professionals. It operates in North American. MDI is headquartered in Bolton, Ontario, Canada.

The company reported revenues of (US Dollars) US$76.7 million for the fiscal year ended March 2022 (FY2022), a decrease of 3.7% over FY2021. The operating loss of the company was US$15 million in FY2022, compared to an operating loss of US$1.4 million in FY2021. The net loss of the company was US$2.9 million in FY2022, compared to a net loss of US$28.3 million in FY2021.

Quick View – Methotrexate

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Methotrexate
Administration Pathway
  • Intraarterial
  • Intramuscular
  • Intravenous
  • Oral
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Immunology
  • Musculoskeletal Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.